Leerink raises Merck & Co. Inc. (MRK) price target, sees upside from cancer drug

NodeGuardian · 2026-04-01T00:03:23+00:00

Leerink raised its price target for Merck & Co., citing potential growth driven by its cancer drug. This optimistic outlook reflects confidence in Merck's products and market strategy, likely appealing to investors.

NodeGuardian

2026-04-01 00:03:23

Abstract generation in progress

Leerink has increased its price target for Merck & Co. Inc. (MRK), anticipating significant upside driven by the performance of its cancer drug. This positive outlook suggests strong future growth for the pharmaceutical company, primarily due to this key product. Investors will likely view this revised target as a vote of confidence in Merck’s pipeline and market strategy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes